BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 16785312)

  • 1. Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after Fc gamma RII-mediated uptake.
    Benitez-Ribas D; Adema GJ; Winkels G; Klasen IS; Punt CJ; Figdor CG; de Vries IJ
    J Exp Med; 2006 Jul; 203(7):1629-35. PubMed ID: 16785312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion.
    Tel J; Sittig SP; Blom RA; Cruz LJ; Schreibelt G; Figdor CG; de Vries IJ
    J Immunol; 2013 Nov; 191(10):5005-12. PubMed ID: 24127556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facilitated antigen uptake and timed exposure to TLR ligands dictate the antigen-presenting potential of plasmacytoid DCs.
    Kool M; Geurtsvankessel C; Muskens F; Madeira FB; van Nimwegen M; Kuipers H; Thielemans K; Hoogsteden HC; Hammad H; Lambrecht BN
    J Leukoc Biol; 2011 Dec; 90(6):1177-90. PubMed ID: 21934071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
    de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
    Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dominant expression of the inhibitory FcgammaRIIB prevents antigen presentation by murine plasmacytoid dendritic cells.
    Flores M; Desai DD; Downie M; Liang B; Reilly MP; McKenzie SE; Clynes R
    J Immunol; 2009 Dec; 183(11):7129-39. PubMed ID: 19917701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pDCs efficiently process synthetic long peptides to induce functional virus- and tumour-specific T-cell responses.
    Aspord C; Leloup C; Reche S; Plumas J
    Eur J Immunol; 2014 Oct; 44(10):2880-92. PubMed ID: 25043392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen.
    Tel J; Lambeck AJ; Cruz LJ; Tacken PJ; de Vries IJ; Figdor CG
    J Immunol; 2010 Apr; 184(8):4276-83. PubMed ID: 20304825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells.
    Loré K; Smed-Sörensen A; Vasudevan J; Mascola JR; Koup RA
    J Exp Med; 2005 Jun; 201(12):2023-33. PubMed ID: 15967828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low responsiveness of hepatitis B virus-transgenic mice in antibody response to T-cell-dependent antigen: defect in antigen-presenting activity of dendritic cells.
    Akbar SM; Onji M; Inaba K; Yamamura K; Ohta Y
    Immunology; 1993 Mar; 78(3):468-75. PubMed ID: 8478028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of antigen-specific CD4+ T cell lines from naive precursors.
    Mehta-Damani A; Markowicz S; Engleman EG
    Eur J Immunol; 1995 May; 25(5):1206-11. PubMed ID: 7774624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
    Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
    Jacobs JF; Punt CJ; Lesterhuis WJ; Sutmuller RP; Brouwer HM; Scharenborg NM; Klasen IS; Hilbrands LB; Figdor CG; de Vries IJ; Adema GJ
    Clin Cancer Res; 2010 Oct; 16(20):5067-78. PubMed ID: 20736326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes.
    Berlyn KA; Schultes B; Leveugle B; Noujaim AA; Alexander RB; Mann DL
    Clin Immunol; 2001 Dec; 101(3):276-83. PubMed ID: 11726219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen crosspresentation by human plasmacytoid dendritic cells.
    Hoeffel G; Ripoche AC; Matheoud D; Nascimbeni M; Escriou N; Lebon P; Heshmati F; Guillet JG; Gannagé M; Caillat-Zucman S; Casartelli N; Schwartz O; De la Salle H; Hanau D; Hosmalin A; Marañón C
    Immunity; 2007 Sep; 27(3):481-92. PubMed ID: 17869134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients.
    Tel J; Aarntzen EH; Baba T; Schreibelt G; Schulte BM; Benitez-Ribas D; Boerman OC; Croockewit S; Oyen WJ; van Rossum M; Winkels G; Coulie PG; Punt CJ; Figdor CG; de Vries IJ
    Cancer Res; 2013 Feb; 73(3):1063-75. PubMed ID: 23345163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of human plasmacytoid dendritic cells by TLR9 impairs Fc gammaRII-mediated uptake of immune complexes and presentation by MHC class II.
    Benitez-Ribas D; Tacken P; Punt CJ; de Vries IJ; Figdor CG
    J Immunol; 2008 Oct; 181(8):5219-24. PubMed ID: 18832675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-4 synthesis by in vivo primed keyhole limpet hemocyanin-specific CD4+ T cells. I. Influence of antigen concentration and antigen-presenting cell type.
    DeKruyff RH; Fang Y; Umetsu DT
    J Immunol; 1992 Dec; 149(11):3468-76. PubMed ID: 1358971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
    Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM
    Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BDCA-2 signaling inhibits TLR-9-agonist-induced plasmacytoid dendritic cell activation and antigen presentation.
    Jähn PS; Zänker KS; Schmitz J; Dzionek A
    Cell Immunol; 2010; 265(1):15-22. PubMed ID: 20673884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.